½ÃÀ庸°í¼­
»óǰÄÚµå
1642691

¿©¼º °Ç°­ ½ÃÀå º¸°í¼­ : ¿¬·ÉÃþº°, ¿ëµµº°, À¯Åë ä³Îº°, Áö¿ªº°(2025-2033³â)

Women¢¥s Health Market Report by Age Group Type, Application, Distribution Channel, and Region 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 133 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¿©¼º °Ç°­ ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 426¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â±îÁö ½ÃÀåÀº 595¾ï ´Þ·¯¿¡ ´ÞÇϸç, 2025-2033³âÀÇ ¼ºÀå·ü(CAGR)Àº 3.59%¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. °í·É ¿©¼º Àα¸ÀÇ Áõ°¡, ³ëÈ­¿¡ ¼ö¹ÝÇϴ ƯÀ¯ÀÇ °Ç°­ ¿ä±¸, ¿©¼º °Ç°­¿¡ ´ëÇÑ »çȸ±Ô¹ü ¹× ŵµÀÇ º¯È­, ÇコÄÉ¾î ¼­ºñ½º¿¡ ´ëÇÑ ¾×¼¼½º Çâ»óÀ» À§ÇÑ ÀÚ±ÝÁ¶´ÞÀÇ Áõ°¡ µîÀÌ ½ÃÀåÀ» ÃßÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ÇöÀç ºÏ¹Ì°¡ ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¿©¼º »çÀÌ¿¡¼­ ¿¹¹æ ÇコÄÉ¾î ´ëÃ¥¿¡ ´ëÇÑ ÀǽÄÀÇ Çâ»ó°ú ÁßÁ¡ÀÌ ¹è°æ¿¡ ÀÖ½À´Ï´Ù.

¿©¼º °Ç°­Àº ¿©¼ºÀÇ ½ÅüÀû, Á¤½ÅÀû À£ºù¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Áúº´°ú »óÅÂÀÇ Ä¡·á¿Í Áø´Ü¿¡ ÃÊÁ¡À» ¸ÂÃá ÀÇÇÐÀÇ ÇÑ ºÐ¾ßÀÔ´Ï´Ù. »ý½Ä °Ç°­, ÀÓ»êºÎ °Ç°­, Á¤½Å°Ç°­, ºñ°¨¿°¼º Áúȯ µî ¿©¼º¿¡°Ô Å« ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Â ´Ù¾çÇÑ Àü¹® ºÐ¾ß¿Í ÁßÁ¡ ºÐ¾ß¸¦ Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ´Â ¿©¼º °³ÀÎÀÇ Çູ¿¡ ÇʼöÀûÀÏ »Ó¸¸ ¾Æ´Ï¶ó °æÁ¦Àû »ý»ê¼º, °¡Á· ¾ÈÁ¤¼º, °øÁß º¸°ÇÀÇ °á°ú¿Í °ü·ÃµÈ ´õ ³ÐÀº »çȸÀû Àǹ̵µ °¡Áö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ¹®Á¦´Â »ý¹°ÇÐÀû ¿äÀλӸ¸ ¾Æ´Ï¶ó »çȸÀû ±Ô¹ü, »ýȰ¾ç½Ä ¼±ÅÃ, ÀÇ·á ¼­ºñ½º À̿뿡¼­ÀÇ ¼ºº° Â÷ÀÌ¿¡ ¿µÇâÀ» ¹Þ´Â´Ù´Â Á¡¿¡ À¯ÀÇÇÏ´Â °ÍÀÌ Áß¿äÇÕ´Ï´Ù. µû¶ó¼­ ¿©¼º °Ç°­¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ Á¢±ÙÀ» À§Çؼ­´Â ÀÌ·¯ÇÑ ´Ù¸éÀû Ãø¸éÀ» ÀÌÇØÇϰí À̸¦ ÇØ°áÇØ¾ß ÇÕ´Ï´Ù.

¿©¼ºÀÇ °í·ÉÈ­´Â ¿©¼º °Ç°­ ½ÃÀåÀÇ Áß¿äÇÑ ¿øµ¿·ÂÀÔ´Ï´Ù. ¿©¼ºÀº ³ªÀ̰¡ µé¾î°¨¿¡ µû¶ó Æó°æ, °ñ´Ù°øÁõ, ½ÉÀ庴, ÀϺΠ¾Ï°ú °°Àº µ¶Æ¯ÇÑ °Ç°­ ¹®Á¦¿¡ Á÷¸éÇÏ°Ô µË´Ï´Ù. ÀÌó·³ Àü ¼¼°è¿¡¼­ °í·É ¿©¼º Àα¸°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, °í·ÉÈ­¿¡ µû¸¥ ƯÀ¯ÀÇ °Ç°­ ¿ä±¸´Â ¼­ºñ½º ¹× Á¦Ç°¿¡ ´ëÇÑ °­·ÂÇÑ ¼ö¿ä¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² ¿©¼º °Ç°­¿¡ ´ëÇÑ »çȸÀû ±Ô¹ü°ú »ç°í¹æ½ÄÀÇ º¯È­µµ ÀÌ »ê¾÷ÀÇ Áß¿äÇÑ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. µû¶ó¼­ ¼ºº°·Î ƯȭµÈ ÇコÄɾ ´ëÇÑ ±Ç¸®¿Í Çʿ伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àü ¼¼°è ÀÇ·áºñ ÁöÃâ Áõ°¡µµ ¿©¼º °Ç°­ ½ÃÀåÀÇ ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¼Òµæ ¼öÁØÀÌ ³ô¾ÆÁü¿¡ µû¶ó °³Àΰú °¡Á·Àº ¿¹¹æ ¹× Ä¡·á ÀÇ·á¿¡ ÅõÀÚÇÏ´Â °æÇâÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¤ºÎµµ ´õ ¸¹Àº ¿¹»êÀ» ÇコÄɾ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÚ±Ý Áö¿øÀº ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ³ôÀÌ°í ¿©¼º °Ç°­ÄÉ¾î ¿¬±¸ ¹× Á¦Ç° °³¹ßÀÇ ÁøÀüÀ» ÃËÁøÇÕ´Ï´Ù.

¿©¼º °Ç°­ ½ÃÀå µ¿Çâ/ÃËÁø¿äÀÎ:

ÀÎ½Ä Á¦°í¿Í Á¤ºÎÀÇ ±¸»ó

Áö³­ ¼ö³â°£ ¼¼°è °¢±¹ÀÇ Á¤ºÎ, ºñ¿µ¸®´Üü ¹× ±¹Á¦±â±¸´Â ¿©¼º °Ç°­ ¹®Á¦¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀÌ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇØ¿Ô½À´Ï´Ù. ÀÌ´Â ÁÖ·Î Ä·ÆäÀÎ, Á¤Ã¥ º¯°æ, ¿¬±¸ ¹× ¼­ºñ½º ÀÚ±Ý Áö¿øÀ» ÅëÇØ ÀÌ·ç¾îÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ ³ë·ÂÀº ¿©¼º °Ç°­ ¹®Á¦°¡ Àü ¼¼°è¿¡¼­ ÁÖ¸ñ¹Þ´Â ȯ°æÀ» Á¶¼ºÇÏ°í ¿©¼º °Ç°­ Á¦Ç° ¹× ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½ÃŰ´Â µ¥ ±â¿©Çß½À´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ Á¤ºÎÀÇ ±¸»óÀº Á¾Á¾ °Ç°­ °ËÁø, Áø´Ü Å×½ºÆ® ¹× ¿¹¹æ Á¶Ä¡¿¡ ´ëÇÑ ±ÔÁ¤À» Æ÷ÇÔÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¾÷°èÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ´Ù¾çÇÑ Á¤ºÎ ¹ý·üÀº °Ç°­ º¸ÇèÀ» ÅëÇÑ ¿¹¹æ ¼­ºñ½º Á¦°øÀ» Àǹ«È­Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ÀÌ·¯ÇÑ ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁõÆø½Ã۰í ÀÖ½À´Ï´Ù.

²÷ÀÓ¾ø´Â ±â¼ú ¹ßÀü

±â¼úÀÇ ±Þ¼ÓÇÑ ¹ßÀüÀº ¿©¼º °Ç°­ »ê¾÷¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Áø´Ü Åø¿Í Ä¡·á¹ýµµ ÁøÈ­ÇÏ°í °³¼±µÇ¾î ´õ ³ªÀº Áúº´ ¹ß°ß, ´õ È¿°úÀûÀÎ Ä¡·á, »ýÁ¸À² Çâ»óÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ÅÚ·¹Çコ, ¸ð¹ÙÀÏ ¾Û, ¿þ¾î·¯ºí ±â±â µî µðÁöÅÐ °Ç°­ ±â¼úÀº ÇöÀç ¿©¼º °Ç°­ »óŸ¦ º¸´Ù È¿À²ÀûÀ¸·Î ÃßÀûÇÏ°í °ü¸®ÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ÀΰøÁö´É°ú ¸Ó½Å·¯´×À» Æ÷ÇÔÇÑ Ã·´Ü ±â¼úµµ ´Ù¾çÇÑ °ü·Ã ¹®Á¦¸¦ Áø´ÜÇϰí Ä¡·áÇÏ´Â µ¥ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú ¹ßÀüÀº ¿©¼º¿¡°Ô º¸´Ù È¿°úÀûÀÌ°í °³ÀÎÈ­µÈ ÇコÄÉ¾î ¼Ö·ç¼ÇÀ» º¸ÀåÇÒ »Ó¸¸ ¾Æ´Ï¶ó »õ·Î¿î ±âȸ¿Í ¼ö¿ä¸¦ âÃâÇÏ¿© ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀÔ´Ï´Ù.

¸¸¼ºÁúȯ Áõ°¡

¾Ï(ƯÈ÷ À¯¹æ¾Ï°ú ÀڱðæºÎ¾Ï), ½ÉÇ÷°ü Áúȯ, ´ç´¢º´, °ñ´Ù°øÁõ µî ¿©¼ºÀÇ ¸¸¼ºÁúȯ ¹ßº´·ü Áõ°¡·Î ÀÎÇØ ÀÌ·¯ÇÑ ¼­ºñ½ºÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é ºñ°¨¿°¼º Áúȯ, ƯÈ÷ ¾Ï°ú ½ÉÇ÷°ü ÁúȯÀº Àü ¼¼°è ¿©¼º »ç¸Á¿øÀÎÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÕ´Ï´Ù. ÀÌ¿Í ÇÔ²² ¿©¼º ¸¸¼ºÁúȯÀÇ ³î¶ó¿î Áõ°¡´Â Àû½Ã¿¡ ¹ß°ß, È¿°úÀûÀÎ Ä¡·á ¿É¼Ç, ¿¹¹æ Ä¡·á Áõ°¡¸¦ ÇÊ¿ä·Î Çϸç, ÀÌ´Â ¿©¼º °Ç°­ »ê¾÷ÀÇ ÁÖ¿ä ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ »ý½Ä °Ç°­Àº ¿©ÀüÈ÷ ½ÃÀåÀÇ Áß¿äÇÑ Ãø¸éÀÔ´Ï´Ù. »ê¸ð »ç¸Á·ü°ú ¿µ¾Æ »ç¸Á·üÀ» ³·Ãß±â À§ÇØ °¡Á· °èȹ ¼­ºñ½º, »êÀü °ü¸®, ¾ÈÀüÇÑ Ãâ»ê ¹æ¹ý¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» °­Á¶ÇÏ´Â °æÇâÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå¿¡ ´õ ¸¹Àº ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»çÀÇ ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • º¸ÅÒ¾÷ ¾îÇÁ·ÎÄ¡
    • Åé´Ù¿î ¾îÇÁ·ÎÄ¡
  • Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ¼­·Ð

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ¿©¼º °Ç°­ ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : ¿¬·Éº°

  • 50¼¼ ÀÌ»ó
    • ½ÃÀå µ¿Çâ
    • ÁÖ¿ä ºÎ¹®
      • Æó°æ ÈÄ °ñ´Ù°øÁõ
      • Àڱ󻸷Áõ°ú ÀڱñÙÁ¾
      • Æó°æ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦7Àå ½ÃÀå ³»¿ª : ¿ëµµº°

  • ÇÇÀÓ¾à
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • °ñ´Ù°øÁõ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Æó°æ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ºÒÀÓ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦8Àå ½ÃÀå ³»¿ª : À¯Åë ä³Îº°

  • º´¿ø ¾à±¹
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¼Ò¸Å ¾à±¹
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¿Â¶óÀÎ ¾à±¹
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦9Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ³»¿ª : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦10Àå ÃËÁø¿äÀΡ¤¾ïÁ¦¿äÀΡ¤±âȸ

  • °³¿ä
  • ÃËÁø¿äÀÎ
  • ¾ïÁ¦¿äÀÎ
  • ±âȸ

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ¹ÙÀ̾îÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀïÀÇ Á¤µµ
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ÀÇ °³¿ä
    • Abbott Laboratories
    • AbbVie Inc.
    • Agile Therapeutics Inc.
    • Amgen Inc.
    • Bayer AG
    • F. Hoffmann-La Roche AG
    • Ferring Pharmaceuticals
    • FUJIFILM Holdings Corporation
    • Hologic Inc.
    • Lupin Limited
    • Novo Nordisk A/S
    • Pfizer Inc.
KSA 25.03.10

The global women's health market size reached USD 42.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 59.5 Billion by 2033, exhibiting a growth rate (CAGR) of 3.59% during 2025-2033. The growing population of elderly women, and the specific health needs associated with aging, changing societal norms and attitudes towards women's health, and the rising funding for better access to healthcare services are some of the major factors propelling the market. At present, North America holds the largest market share, driven by the increasing awareness and focus on preventive healthcare measures among women.

Women's health refers to the branch of medicine that focuses on the treatment and diagnosis of diseases and conditions that affect a woman's physical and emotional well-being. It encompasses a broad range of specialties and focus areas, such as reproductive health, maternal health, mental health, and non-communicable diseases, which can all significantly impact women. It is vital not only for the individual well-being of women, but it also has wider societal implications relating to economic productivity, family stability, and public health outcomes. Furthermore, it's important to note that these issues are influenced by biological factors as well as gender-related differences in societal norms, lifestyle choices, and access to healthcare. Thus, a comprehensive approach to women's health necessitates understanding and addressing these multifaceted dimensions.

The aging female population is a key driver of the women's health market. As women age, they face a specific set of health challenges including menopause, osteoporosis, heart disease, and certain types of cancer. This increasing population of elderly women globally, and the specific health needs associated with aging, create a robust demand for services and products. Along with this, changing societal norms and attitudes towards women's health have also acted as a significant driver in this industry. Therefore, the growing recognition of rights and the need for gender-specific healthcare is positively influencing the market. In addition, the rise in healthcare spending across the globe also contributes significantly to the growth of the women's health market. With higher income levels, individuals and families are more inclined to invest in preventive and curative healthcare. Governments, too, are dedicating larger portions of their budgets towards healthcare. This accelerated funding allows for better access to healthcare services and promotes advancements in women's healthcare research and product development.

Women's Health Market Trends/Drivers:

Increased Awareness and Government Initiatives

Over the past few years, governments across the globe, non-profit organizations, and international agencies have played an instrumental role in heightening awareness about women's health issues. This has been primarily achieved through campaigns, policy changes, and funding for research and services. These initiatives have fostered an environment where health matters are gaining global attention, leading to increased demand for women's health products and services. Moreover, these government initiatives often include provisions for health screenings, diagnostic tests, and preventive measures, which further drive the growth of the industry. Various government acts, for instance, make preventative services for a mandatory health insurance provision, amplifying the demand for such services.

Continuous Advancements in Technology

The rapid advancement in technology has significantly impacted the women's health industry. Along with this, diagnostic tools and therapies have evolved and improved, which have led to better disease detection, more effective treatments, and increased survival rates. Digital health technologies, such as telehealth, mobile apps, and wearable devices are now assisting women in tracking and managing their health more efficiently. Advanced technologies, including artificial intelligence and machine learning, are also being employed in the diagnosis and treatment of various related issues. These technological advancements ensure more effective and personalized healthcare solutions for women but also stimulate the market's growth by creating new opportunities and demands.

Rising Incidences of Chronic Diseases

An increasing incidence of chronic diseases among women, such as cancer (specifically breast and cervical cancer), cardiovascular diseases, diabetes, and osteoporosis, is driving the need for these services. According to global health organizations, non-communicable diseases, notably cancer, and cardiovascular diseases, are responsible for the majority of deaths among women across the globe. In confluence with this, this alarming rise in chronic conditions among women necessitates timely detection, effective treatment options, and increased preventive care, which are the major propellers for the women's health industry. Also, reproductive health remains a significant aspect of the market. The industry is witnessing a growing emphasis on access to family planning services, prenatal care, and safe childbirth practices to reduce maternal and infant mortality rates, further impacting the market.

Women's Health Industry Segmentation:

Breakup by Age Group Type:

50 Years and Above

Postmenopausal Osteoporosis

Endometriosis and Uterine Fibroids

Menopause

Others

50 Years and Above dominate the market

The 50 years and above age group in the industry has witnessed significant market drivers over the past decades. One of the primary factors contributing to this trend is the global demographic shift towards an aging population, leading to an increased number of women entering this age bracket. Additionally, advancements in healthcare technology and increased access to medical services have enabled better diagnoses and treatments for age-related health conditions in women. In addition, the growing awareness among this demographic regarding preventive healthcare measures and wellness has influenced the demand for specialized products and services catering to their unique needs. As women in this age group seek to maintain their health and quality of life, there is an escalating demand for menopause-related treatments, bone health supplements, and preventive screenings. This market segment's potential for growth is further bolstered by the expanding focus on research, allowing the industry to offer targeted and evidence-based solutions.

Breakup by Application:

Contraceptives

Osteoporosis

Menopause

Infertility

Others

Contraceptives dominate the market

The industry has been significantly influenced by the increasing global awareness of family planning and reproductive health. Governments, organizations, and healthcare providers are emphasizing the importance of safe and effective contraceptive methods to empower women to make informed choices about their reproductive health. Additionally, advancements in medical technology have led to the development of a wide range of contraceptive options, offering women more choices and personalized solutions to suit their preferences and needs. In confluence with this, the shifting societal attitudes towards women's rights and gender equality have resulted in greater access to contraceptive products and services, enabling women to take control of their reproductive decisions. Furthermore, the growing prevalence of sexually transmitted infections has reinforced the importance of using contraceptives as a means of protection.

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Hospital pharmacies dominate the market

The hospital pharmacies distribution channel in the industry is experiencing significant market drivers that shape its growth and development. One of the key factors contributing to the prominence of this distribution channel is the rising demand for specialized women's health medications and treatments within hospital settings. Hospitals serve as essential centers for comprehensive medical care, making them an ideal platform to provide a wide range of women's health products, including contraceptives, hormone therapies, fertility medications, and prenatal supplements. Additionally, the increasing prevalence of chronic conditions, such as gynecological disorders and menopause-related symptoms, has led to a growing need for prompt access to medications and treatments, which hospital pharmacies can efficiently cater to. Furthermore, regulatory initiatives and healthcare policies that encourage hospitals to maintain well-stocked pharmacies with a focus on women's health contribute to the expansion of this distribution channel.

Breakup by Region:

North America

United States

Canada

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The industry in North America is influenced by the region's aging population. It contributes to an increased demand for women's health services and products catering to menopausal and post-menopausal women. Additionally, the growing awareness and emphasis on preventive healthcare measures among women drive the market for screenings, wellness programs, and specialized treatments. In addition, advancements in medical research and technology facilitate the development of innovative solutions, encouraging investment and competition in the industry.

Moreover, favorable healthcare policies and insurance coverage for women's health services bolster market growth. Apart from this, shifting cultural attitudes towards women's empowerment and gender equality enhances access to comprehensive healthcare, including family planning and contraceptive options. Furthermore, strategic marketing efforts and educational campaigns by industry players to promote health and wellness further fuel market expansion.

Competitive Landscape:

The global women's health market is experiencing significant growth due to the growing investments in research and development to create new and improved women's health products, including contraceptives, fertility treatments, hormone therapies, prenatal vitamins, and other related medications. Along with this, companies are promoting their women's health products and services through marketing campaigns to grow awareness among healthcare providers and consumers. These campaigns often focus on promoting the benefits and efficacy of their offerings. Numerous companies are forming partnerships with healthcare providers, clinics, hospitals, and other organizations to expand their market reach and enhance distribution channels, impacting the market. Moreover, the introduction of educational programs for healthcare professionals to ensure proper understanding and usage of their products is contributing to the market.

The report has provided a comprehensive analysis of the competitive landscape in the global women's health market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Abbott Laboratories

AbbVie Inc.

Agile Therapeutics Inc.

Amgen Inc.

Bayer AG

Hoffmann-La Roche AG

Ferring Pharmaceuticals

FUJIFILM Holdings Corporation

Hologic Inc.

Lupin Limited

Novo Nordisk A/S

Pfizer Inc.

Key Questions Answered in This Report:

  • How has the global women's health market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global women's health market?
  • What is the impact of each driver, restraint, and opportunity on the global women's health market?
  • What are the key regional markets?
  • Which countries represent the most attractive women's health market?
  • What is the breakup of the market based on the age group?
  • Which is the most attractive age group in the women's health market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the women's health market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the women's health market?
  • What is the competitive structure of the global women's health market?
  • Who are the key players/companies in the global women's health market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Women's Health Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Age Group

  • 6.1 50 Years and Above
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Postmenopausal Osteoporosis
      • 6.1.2.2 Endometriosis and Uterine Fibroids
      • 6.1.2.3 Menopause
    • 6.1.3 Market Forecast
  • 6.2 Others
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Contraceptives
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Osteoporosis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Menopause
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Infertility
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AbbVie Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Agile Therapeutics Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 Amgen Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Bayer AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 F. Hoffmann-La Roche AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Ferring Pharmaceuticals
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 FUJIFILM Holdings Corporation
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Hologic Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Lupin Limited
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Novo Nordisk A/S
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Pfizer Inc.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦